Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen Sells 1,664 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 1,664 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $11.20, for a total transaction of $18,636.80. Following the completion of the transaction, the chief executive officer now directly owns 77,454 shares of the company’s stock, valued at $867,484.80. This represents a 2.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Atara Biotherapeutics Trading Down 2.8 %

ATRA opened at $10.68 on Thursday. The firm’s 50 day moving average is $9.14 and its 200-day moving average is $10.11. Atara Biotherapeutics, Inc. has a 52-week low of $6.50 and a 52-week high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the previous year, the firm earned ($16.50) earnings per share. On average, sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Hedge funds have recently modified their holdings of the stock. Delap Wealth Advisory LLC purchased a new stake in shares of Atara Biotherapeutics in the first quarter worth approximately $29,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth about $53,000. Cubist Systematic Strategies LLC acquired a new position in Atara Biotherapeutics in the second quarter worth approximately $79,000. State Street Corp lifted its stake in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares during the last quarter. Finally, FMR LLC increased its stake in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares during the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ATRA shares. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Canaccord Genuity Group raised their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price target for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.